Stability of the vasopressin V 2 receptor-adenylyl cyclase system in rat kidney

By Shen T.   Laycock J.   Suzuki Y.   Defer N.   Hanoune J.  

European Journal of Pharmacology, Vol. 341, Iss. 1, 1998-01 ,pp. : 87-94

Elsevier

Access to resources Recommend Favorite

The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 3, 2003-06 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists

By Hagiwara Yohsuke  

Expert Opinion on Drug Discovery, Vol. 8, Iss. 8, 2013-11 ,pp. : 951-964

Informa Healthcare

Access to resources Recommend Favorite

In vivo and in vitro characterisation of a nonpeptide vasopressin V 1A and V 2 receptor antagonist (YM087) in the rat

By Risvanis J.   Naitoh M.   Johnston C.I.   Burrell L.M.  

European Journal of Pharmacology, Vol. 381, Iss. 1, 1999-09 ,pp. : 23-30

Elsevier

Access to resources Recommend Favorite

Pharmacological characterization of YM471, a novel potent vasopressin V 1A and V 2 receptor antagonist

By Tsukada J.   Tahara A.   Tomura Y.   Wada K.-i.   Kusayama T.   Ishii N.   Aoki M.   Yatsu T.   Uchida W.   Taniguchi N.   Tanaka A.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 129-138

Elsevier

Access to resources Recommend Favorite